Picoliter-droplet digital polymerase chain reaction-based analysis of cell-free plasma DNA to assess EGFR mutations in lung adenocarcinoma that confer resistance to tyrosine-kinase inhibitors

Oncologist

Volumn 21, Issue 2, 2016, Pages 156-164

  Seki, Yoshitaka ^a,b   Fujiwara, Yutaka ^c   Kohno, Takashi ^a   Takai, Erina ^a   Sunami, Kuniko ^c   Goto, Yasushi ^c   Horinouchi, Hidehito ^c   Kanda, Shintaro ^c   Nokihara, Hiroshi ^c   Watanabe, Shun Ichi ^c   Ichikawa, Hitoshi ^a   Yamamoto, Noboru ^c   Kuwano, Kazuyoshi ^b   Ohe, Yuichiro ^c  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acquired resistance; Cell free DNA; Digital PCR; EGFR tyrosine kinase inhibitor; Lung cancer; Next generation sequencing

Indexed keywords

AFATINIB; CIRCULATING PLASMA CELL FREE DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; OSIMERTINIB; ROCILETINIB; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DNA DETERMINATION; DRUG SENSITIVITY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; PHASE 1 CLINICAL TRIAL (TOPIC); PICOLITER DROPLET DIGITAL POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR GROWTH; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG RESISTANCE; GENETICS; ISOLATION AND PURIFICATION; LUNG TUMOR; MUTATION; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84957547821     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0288     Document Type: Article

References (44)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlyingresponsivenessofnon-small-celllungcancer to gefitinib. N Engl J Med 2004;350:2129–2139.
2. Ciardiello F, Tortora G. EGFRantagonists incancer treatment. N Engl J Med 2008;358:1160–1174.
3. Diaz LA Jr., Williams RT, Wu J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537–540.
4. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. NEngl JMed 2013;368:842–851.
5. Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquiredresistanceto EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240–2247.
6. Cross DAE, Ashton SE, Ghiorghiu S et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046–1061.
7. Walter AO, Sjin RTT, Haringsma HJ et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013;3:1404–1415.
8. Tjin Tham Sjin R, Lee K, Walter AO et al. In vitro and in vivo characterization of irreversible mutantselective EGFR inhibitors that are wild-type sparing. Mol Cancer Ther 2014;13:1468–1479.
9. Lee K-O, Cha MY, Kim M et al. Abstract LB-100: Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor. Cancer Res 2014; 74:LB–100.
10. Sacher AG, Jänne PA, Oxnard GR. Managementof acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced nonsmall cell lung cancer. Cancer 2014;120:2289–2298.
11. Walsh K, Wallace WA, Butler R et al. A cautionary lesson on the use of targeted methods for EGFR mutation analysis: A case report. J Clin Pathol 2014;67:734–735.
12. Leary RJ, Sausen M, Kinde I et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4:162ra154.
13. Forshew T, Murtaza M, Parkinson C et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68–136ra68.
14. Chan KCA, Jiang P, Zheng YWL et al. Cancer genome scanning in plasma: Detection of tumorassociatedcopynumberaberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59:211–224.
15. Yong E. Cancer biomarkers: Written in blood. Nature 2014;511:524–526.
16. Heitzer E, Ulz P, Geigl JB. CirculatingtumorDNA as a liquid biopsy for cancer. Clin Chem 2015;61: 112–123.
17. Oxnard GR, Paweletz CP, Kuang Y et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative nextgeneration genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698–1705.
18. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823–859.
19. Murtaza M, Dawson S-J, Tsui DWY et al. Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497:108–112.
20. Gao F, Pfeifer E, Farah H et al. Microdroplet digital PCR: Detection and quantitation of biomarkers inarchivedtissueandserialplasmasamples inpatients with lung cancer. J Thorac Oncol 2015;10:212–217.
21. Kukita Y, Uchida J, Oba S et al. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencingdata. PLoSOne 2013;8:e81468.
22. Newman AM, Bratman SV, To J et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548–554.
23. Mok T, Wu Y-L, Lee J-S et al. Detection and dynamic changes of EGFR mutations from circulating tumorDNAas a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 2015; 21:3196–3203.
24. Watanabe M, Kawaguchi T, Isa S et al. Ultrasensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin Cancer Res 2015;21:3552–3560.
25. Chung K-P, Wu S-G, Wu J-Y et al. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Clin Cancer Res 2012;18:3470–3477.
26. Yung TKF, Chan KCA, Mok TSK et al. Singlemolecule detection of epidermal growth factor receptormutationsinplasmabymicrofluidics digitalPCR in non-small cell lung cancer patients. Clin Cancer Res 2009;15:2076–2084.
27. Taly V, Pekin D, Benhaim L et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013;59:1722–1731.
28. Didelot A, Kotsopoulos SK, Lupo A et al. Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples. Clin Chem 2013;59:815–823.
29. Laurent-Puig P, Pekin D, Normand C et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 2015;21:1087–1097.
30. Oike T, Ogiwara H, Tominaga Y et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res 2013;73:5508–5518.
31. Suzuki A, Makinoshima H, Wakaguri H et al. Aberrant transcriptional regulations in cancers: Genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids Res 2014;42: 13557–13572.
32. Blanco R, Iwakawa R, Tang M et al. A genealteration profile of human lung cancer cell lines. Hum Mutat 2009;30:1199–1206.
33. Huggett JF, Foy CA, Benes V et al. The digital MIQE guidelines: Minimum information for publication of quantitative digital PCR experiments. Clin Chem 2013;59:892–902.
34. Zheng C, Sun Y-H, Ye X-L et al. Establishment andcharacterization of primary lung cancer cell lines from Chinese population. Acta Pharmacol Sin 2011; 32:385–392.
35. Nagai Y, Miyazawa H, Huqun et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276–7282.
36. Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. AmSoc Clin Oncol Educ Book 2014;34:e353–e365.
37. Ishii H, Azuma K, Sakai K et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget 2015;6:30850–30858.
38. Crowley E, Di Nicolantonio F, Loupakis F et al. Liquid biopsy: Monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472–484.
39. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013;31:3987–3996.
40. Yu HA, Riely GJ, Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 2014;20: 5898–5907.
41. Wu J-Y, Yu C-J, Chang Y-C et al. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance innon-small cell lung cancer. Clin Cancer Res 2011;17:3812–3821.
42. Uramoto H, Iwata T, Onitsuka T et al. Epithelialmesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 2010; 30:2513–2517.
43. Suda K, Tomizawa K, Fujii M et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2011; 6:1152–1161.
44. Taniguchi K, Uchida J, Nishino K et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011;17:7808–7815.